PMID- 22345625
OWN - NLM
STAT- MEDLINE
DCOM- 20121003
LR  - 20120220
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Linking)
VI  - 17
IP  - 6
DP  - 2011 Nov-Dec
TI  - Assessment of HIT antibody complex in hip fracture patients receiving enoxaparin 
      or unfractionated heparin.
PG  - 567-71
LID - 10.1177/1076029611398121 [doi]
AB  - Thromboembolic disease is a common complication of hip fracture in the elderly. 
      Anticoagulants represent a standard of care in preventing postoperative 
      thrombotic complications following surgical fixation. We asked whether levels of 
      antibody to heparin-platelet factor 4 (PF4) complex were differentially present 
      in unfractionated heparin (UFH) versus Enoxaparin, following hip fracture and 
      whether one particular subtype of antibodies was more prevalent. Plasma samples 
      from elderly patients sustaining a hip fracture treated with either enoxaparin or 
      UFH were collected pre- and postoperatively and analyzed using enzyme-linked 
      immunosorbent assay (ELISA) sandwich method for the prevalence of antiheparin-PF4 
      antibodies and later subtyped. The prevalence of antiheparin-PF4 antibodies was 
      higher in the UFH group especially on postoperative day 7. Patients treated with 
      UFH showed a greater prevalence of antiheparin-PF4 antibodies and a greater 
      prevalence of immunoglobulin G (IgG) subtype. Heparin and enoxaparin are capable 
      of generating heparin-induced thrombocytopenia (HIT) antibodies in elderly 
      patients undergoing orthopedic surgery but perhaps not to the same extent. When 
      comparing low-molecular-weight heparin (LMWH) with UFH, the incidence of new 
      antiheparin-PF4 antibody production is higher in patients treated with UFH.
FAU - Griffin, Justin W
AU  - Griffin JW
AD  - Loyola University Chicago Stritch School of Medicine, 2160 S First Ave, Maywood, 
      IL, USA.
FAU - Hopkinson, William J
AU  - Hopkinson WJ
FAU - Lassen, Michael R
AU  - Lassen MR
FAU - Thethi, Indermohan
AU  - Thethi I
FAU - Litinas, Evangelos
AU  - Litinas E
FAU - Fareed, Jawed
AU  - Fareed J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 0 (Antibodies)
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 37270-94-3 (Platelet Factor 4)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Antibodies/*immunology
MH  - Anticoagulants/adverse effects/therapeutic use
MH  - Enoxaparin/adverse effects/*therapeutic use
MH  - Female
MH  - Heparin/adverse effects/*immunology/therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Hip Fractures/*drug therapy/immunology/surgery
MH  - Humans
MH  - Male
MH  - Platelet Factor 4/*immunology
MH  - Prospective Studies
MH  - Randomized Controlled Trials as Topic
MH  - Thrombosis/drug therapy/etiology/prevention & control
MH  - Venous Thrombosis/drug therapy/etiology/prevention & control
EDAT- 2012/02/22 06:00
MHDA- 2012/10/04 06:00
CRDT- 2012/02/21 06:00
PHST- 2012/02/21 06:00 [entrez]
PHST- 2012/02/22 06:00 [pubmed]
PHST- 2012/10/04 06:00 [medline]
AID - 17/6/567 [pii]
AID - 10.1177/1076029611398121 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):567-71. doi: 
      10.1177/1076029611398121.